Andrzej J Jakubowiak (Andrzej Jakubowiak)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Multiple Myeloma

Affordable Care Act

Prognostic Factors

Stem Cell Transplantation

Top Venues

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej J Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson, Ashraf Z Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British journal of haematology 204 (6) (2024)
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej J Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson, Ashraf Z Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British journal of haematology (2024)
Benjamin A Derman, Spencer S Langerman, Maya Maric, Andrzej J Jakubowiak, Wei Zhang, Brian C-H Chiu
Sex differences in outcomes in multiple myeloma. British journal of haematology 192 (3) (2020)
Benjamin A Derman, Jagoda K Jasielec, Andrzej J Jakubowiak
Clinician attitudes and practices toward measurable residual disease in multiple myeloma. British journal of haematology 190 (3) (2020)
Andrzej J Jakubowiak, Jagoda K Jasielec, Cara A Rosenbaum, Craig E Cole, Ajai Chari, Joseph Mikhael, Jennifer Nam, Amanda McIver, Erica Severson, Leonor A Stephens, Kathryn Tinari, Shaun Rosebeck, Todd M Zimmerman, Tyler Hycner, Agata Turowski, Theodore Karrison, Jeffrey A Zonder
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. British journal of haematology 186 (4) (2019)